In this randomized clinical trial, gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS compared with gefitinib alone in asymptomatic patients with untreated EGFR-mutant NSCLC brain metastases, with manageable adverse events. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.